Many people with chronic kidney disease (CKD) live for decades after diagnosis, especially when it’s caught early. A 50-year-old man with stage 3a CKD (mild to moderate loss of kidney function) has an average life expectancy of about 18 years, while a 50-year-old woman at the same stage can expect roughly 22 years. How long you live depends heavily on what stage you’re in, your age, whether you have other health conditions, and how aggressively you manage the disease.
Life Expectancy by Stage and Age
The most useful survival data comes from a large population registry in Alberta, Canada, which tracked life expectancy across different levels of kidney function, broken down by age and sex. The numbers below represent average remaining years of life.
For people with stage 3a CKD (kidney function at 45 to 59 percent of normal), the outlook is relatively good. A 40-year-old man can expect about 24.5 more years, while a 40-year-old woman can expect about 28.7 years. At age 65, those numbers drop to around 10.9 years for men and 13.4 years for women. These figures are lower than the general population, but they still represent many years of life.
Stage 3b CKD (kidney function at 30 to 44 percent of normal) carries a steeper reduction. A 40-year-old man at this stage has about 14.5 years of remaining life on average, while a 40-year-old woman has about 16.5 years. By age 65, men average 6.6 years and women average 9.4 years. The gap between stages 3a and 3b is substantial, which is why preventing progression matters so much.
Stage 5 CKD, where the kidneys have lost nearly all function, has the shortest survival. One study of 844 patients found that median survival from the point of reaching stage 5 was about 67 months (roughly 5.5 years) for those who started dialysis or received a transplant.
What Happens at Stage 5: Dialysis vs. Conservative Care
When kidney function drops below about 15 percent, you face a major decision: start dialysis, pursue a transplant, or choose conservative management (treating symptoms without dialysis). For most people, dialysis extends life significantly. But for older adults with multiple serious health conditions, the picture is more nuanced.
In patients over 75 with high levels of other illness (such as heart disease, diabetes, and lung problems), dialysis added only about 4 extra months of survival compared to conservative care. That difference was not statistically significant. This finding matters because dialysis requires significant time and energy, typically three sessions per week lasting several hours each, along with dietary restrictions and potential complications. For some elderly patients, conservative care focused on comfort and quality of life can be a reasonable choice.
For younger patients and those without major additional health problems, dialysis and transplantation offer clear survival benefits. Five-year survival on dialysis has generally improved over recent decades, though the COVID-19 pandemic temporarily reversed some of those gains for patients who started treatment around 2017.
Kidney Transplant Changes the Equation
A kidney transplant offers the best long-term outlook for people with stage 5 CKD who are healthy enough for surgery. Transplant recipients consistently survive longer than those who remain on dialysis, and the difference is not small. Access to transplantation varies, though. Among people without diabetes, nearly 47 percent received a transplant within eight years of starting dialysis. For those with diabetic kidney disease, that number dropped to about 19 percent, partly due to higher rates of other health conditions that complicate surgery.
Why the Cause of CKD Matters
Not all kidney disease behaves the same way. You might assume that diabetes-related kidney disease carries the worst prognosis, but the relationship is more complex. Among people with type 2 diabetes who reached dialysis, those whose kidney damage was caused by something other than diabetes itself (such as high blood pressure or glomerular disease) actually had a higher death rate: 34 percent died within two years, compared to 27 percent of those with classic diabetic kidney disease. By six years, 68 percent of the non-diabetic kidney disease group had died versus 62 percent of the diabetic group.
The takeaway isn’t that diabetes is protective. Rather, the specific pattern of kidney damage, the presence of other organ problems, and access to transplantation all interact in ways that make individual prognosis hard to predict from a single label.
What Actually Slows Progression
The most important factor in how long you live with CKD is whether the disease stays at its current stage or progresses to kidney failure. Several interventions have strong evidence behind them.
A newer class of medications originally developed for diabetes (SGLT2 inhibitors) has proven remarkably effective for CKD, even in people without diabetes. In a large meta-analysis of over 92,000 patients, these drugs reduced the risk of kidney failure outcomes by 35 percent and cut the need for dialysis or transplant by 28 percent. They also lowered the risk of death from kidney causes by 73 percent and reduced cardiovascular death by 12 percent. These medications are now a standard part of CKD treatment for many patients.
Dietary protein intake also plays a meaningful role. Current guidelines recommend keeping protein below 0.8 grams per kilogram of body weight per day once kidney function drops below 30 percent, and avoiding high-protein diets (above 1.3 g/kg/day) for anyone with CKD at risk of progression. A Cochrane review of 10 trials found that reducing protein intake to 0.3 to 0.6 g/kg/day led to a 32 percent reduction in the combined risk of kidney failure or death. For a 170-pound person, that means keeping protein under roughly 55 grams per day at the lower end of that range.
Blood pressure control remains foundational. Uncontrolled high blood pressure accelerates kidney damage regardless of the underlying cause of CKD. Managing blood sugar in diabetes, maintaining a healthy weight, and avoiding medications that stress the kidneys (like certain over-the-counter pain relievers) all contribute to slowing progression.
Risk Isn’t Just About Kidney Function
The 2024 international CKD guidelines use a “heat map” that combines two measurements to predict risk: how well your kidneys filter (eGFR) and how much protein leaks into your urine (albuminuria). Someone with mildly reduced kidney function but significant protein in their urine can be at higher risk than someone with more advanced kidney function loss but no protein leakage.
One surprising finding: people with very high kidney filtration rates (above 105 percent of normal), particularly when combined with protein in the urine, may face cardiovascular and mortality risks exceeding those of people with moderate CKD. This “hyperfiltration” pattern can be an early warning sign, especially in people with diabetes or obesity, even though the kidneys appear to be working well on a standard blood test.
What Shapes Your Individual Outlook
Population averages are useful starting points, but your own trajectory depends on several factors working together. Age at diagnosis is the most powerful predictor: a 30-year-old man with stage 3a CKD still has an average of 28 years ahead, while an 80-year-old man at the same stage has about 4.3 years. Women consistently outlive men at every stage and age bracket, by roughly 1 to 5 years depending on the specific combination.
The speed at which your kidney function declines year to year matters more than a single snapshot. Some people remain stable at stage 3 for decades. Others progress to stage 5 within a few years. Tracking your eGFR trend over time, rather than fixating on a single number, gives a much clearer picture of where things are headed. Heart disease, not kidney failure, is actually the leading cause of death in people with CKD stages 3 and 4, which is why cardiovascular risk management is just as important as kidney-specific treatment.